Valuation : Syntara Limited

Market Cap 51.01M 36.71M 31.58M 29.64M 27.12M 50.61M 3.47B 351M 137M 1.77B 138M 135M 5.71B P/E 2027 *
-5.2x
P/E 2028 * -8.67x
Enterprise Value 18.21M 13.1M 11.27M 10.58M 9.68M 18.07M 1.24B 125M 48.74M 633M 49.21M 48.13M 2.04B EV / Sales 2027 *
-
EV / Sales 2028 * 4.71x
Free-Float
72.62%
Yield 2027 *
-
Yield 2028 * -
1 week+4.00%
1 month+1.96%
6 months-18.75%
Current year-25.71%
1 week 0.02
Extreme 0.025
0.03
1 month 0.02
Extreme 0.024
0.04
Current year 0.02
Extreme 0.019
0.04
1 year 0.02
Extreme 0.019
0.04
3 years 0.01
Extreme 0.014
0.1
5 years 0.01
Extreme 0.014
0.15
10 years 0.01
Extreme 0.014
0.37
Manager TitleAgeSince
Chief Executive Officer 64 2013-03-11
Director of Finance/CFO - 2024-08-30
Chief Tech/Sci/R&D Officer - 2022-06-30
Director TitleAgeSince
Director/Board Member 64 2013-03-11
Chairman 68 2023-10-02
Director/Board Member - 2022-12-15
Date Insider Type Main position Quantity % Market Cap. Importance
3/13/25 Buy

Director

9,753,442 0.6008%
9/24/24 Buy

Director

53,571,429 4.1513%
8/12/21 Expiration

Chief Executive Officer

471,000 0.1040%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+4.00%0.00%-36.59% 36.58M
+1.03%-2.05%+39.28%+94.60% 68.87B
+1.31%+0.55%+49.48%+92.12% 65.29B
-1.05%+3.23%-12.68%+375.18% 27.65B
+2.97%-0.10%+41.86%+14.84% 25.77B
-0.87%-7.62%+2.48%-15.65% 26.08B
+1.01%+1.38%+26.48%-17.50% 20.14B
+3.45%-14.83%+225.22%+389.50% 17.03B
+0.77%-4.55%-0.36%+549.41% 15.03B
+0.85%+6.90%+59.83%+165.27% 14.5B
Average +0.94%-2.39%+43.16%+161.12% 28.04B
Weighted average by Cap. +1.00%-2.12%+42.65%+141.98%

Financials

2027 *2028 *
Net sales - 5.5M 3.96M 3.41M 3.2M 2.92M 5.46M 374M 37.8M 14.72M 191M 14.86M 14.54M 616M
Net income -31.85M -22.92M -19.72M -18.5M -16.93M -31.6M -2.17B -219M -85.25M -1.11B -86.06M -84.19M -3.57B -31.5M -22.67M -19.5M -18.3M -16.74M -31.25M -2.14B -216M -84.31M -1.1B -85.12M -83.26M -3.53B
Net Debt -32.8M -23.6M -20.31M -19.06M -17.44M -32.54M -2.23B -225M -87.79M -1.14B -88.63M -86.7M -3.67B -25.1M -18.06M -15.54M -14.58M -13.34M -24.9M -1.71B -173M -67.18M -873M -67.82M -66.35M -2.81B
Logo Syntara Limited
Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing topical pan-LOX inhibitors in scar revision, keloid scarring and scar prevention post-surgery. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.
Employees
-
Date Price Change Volume
26-09-02 A$0.0260 0.00% 414,042
26-09-02 A$0.0260 0.00% 859,687
26-09-01 A$0.0260 0.00% 254,039
26-08-31 A$0.0260 0.00% 2,184,770
26-08-28 A$0.0260 -3.70% 390,803
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0260AUD
Average target price
0.1050AUD
Spread / Average Target
+303.85%

Quarterly revenue - Rate of surprise